XUAB 2069: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

Grant

Date/time Interval

  • February 23, 2021 - February 22, 2025
  • Total Award Amount

  • 129000.00
  • Direct Costs

  • 86868.00
  • Sponsor Award Id

  • 0001033188
  • Contributor

  • Gaurav Goyal   Principal Investigator  
  • Michael Saag M.D.   Investigator  
  • Victor Lin   Investigator